Skip to main content
SpringerLink
Log in

Mammakarzinomrezidiv und metastasiertes Mammakarzinom

  • Chapter
  • First Online:
Therapiehandbuch Gynäkologie und Geburtshilfe

  • 4826 Accesses

Zusammenfassung

Etwa 1/4 der Patientinnen mit diagnostiziertem Mammakarzinom erleiden im Verlauf der Erkrankung trotz adjuvanter Therapie ein Rezidiv. Die Rezidivrate und die Mortalität konnten beim Mammakarzinom in den letzten Jahren durch verbesserte Früherkennung, konsequente adjuvante Chemotherapie, endokrine Therapie sowie die zielgerichteten Substanzen deutlich gesenkt werden. Die Hälfte der Rezidive tritt in den ersten 5 Jahren nach der Operation auf.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ (2009) Changes in estrogen receptor, progesterone receptor and HER-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29(5):1557–1562

    PubMed  Google Scholar 

  • Butters DJ, Ghersi D, Wilcken N, Kirk SJ, Mallon PT (2010) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2010(11):CD003368

    Google Scholar 

  • Carrick S, Ghersi D, Wilcken N, Simes J (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2004(2):CD003374

    Google Scholar 

  • Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009(2):CD003372

    PubMed Central  Google Scholar 

  • Chlebowski RT, Blackburn GL, Thomson CA et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the women’s intervention nutrition study. J Natl Cancer Inst 98:1767–1776

    Article  PubMed  Google Scholar 

  • de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJH (2004) Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A meta-analysis and systematic review. J Clin Oncol 22(19):4010–4018

    Article  PubMed  Google Scholar 

  • Diel IJ, Body JJ, Lichinitser MR et al (2004) MF 4265 study group: improved quality of life for long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712

    Article  CAS  PubMed  Google Scholar 

  • Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106

    Article  Google Scholar 

  • Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P, Stewart F, Todd R, Mowatt G (2012) Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis. Eur J Cancer Aug 17 (Epub ahead of print)

    Google Scholar 

  • Fossati R, Confalonieri C, Torri V, Ghislandi F, Penna A, Pistotti V (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31500 women. J Clin Oncol 16:3439–3460

    Article  CAS  PubMed  Google Scholar 

  • Geller BM, Kerlikowske K, Carney PA et al (2003) Mammography surveillance following breast cancer. Breast C Res Treatment 81(2):107–115

    Article  Google Scholar 

  • Ghersi D, Wilcken N, Simes J, Donoghue E (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2005(2):CD003366

    Google Scholar 

  • Gibson L, Lawrence D, Dawson C, Bliss J (2009) Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009(4):CD003370

    Google Scholar 

  • Holmes MD, Chen WY, Feskanich D et al (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486

    Article  CAS  PubMed  Google Scholar 

  • Ibrahim EM, Al-Homaidh A (2010) Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 28(3):753–765

    Article  PubMed  Google Scholar 

  • Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19(2):343–353

    Article  CAS  PubMed  Google Scholar 

  • Kommission Mamma der AGO e. V. (2011) Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome, 4. Aufl. Zuckschwerdt, München

    Google Scholar 

  • Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie – AGO e. V. (2012) Alle aktuellen Leitlinien. www.ago-online.de/de/fuer-mediziner/leitlinien/Mamma/

  • Kreienberg R, Kopp I, Lorenz W et al (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik und Therapie des Mammakarzinoms der Frau. 1. Aktualisierung. Zuckschwerdt, München

    Google Scholar 

  • Kroenke CH, Fung TT, Hu FB, Holmes MD (2005) Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 23(36):9295–9303

    Article  PubMed  Google Scholar 

  • Kuerer HM (2004) Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer 100(11):2269–2280

    Article  PubMed  Google Scholar 

  • Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415–2429

    Article  CAS  PubMed  Google Scholar 

  • Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133(3):831–841

    Article  PubMed  Google Scholar 

  • McQuay HJ, Collins SL, Carroll D, Moore RA (2004) Radiotherapy for the palliation of painful bone metastases (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester: Wiley (Cochrane Database Syst Rev Issue 2: CD001793)

    Google Scholar 

  • Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  CAS  PubMed  Google Scholar 

  • Panet-Raymond V, Truong PT, Alexander C, Lesperance M, McDonald RE, Watson PH (2011) Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer 117(10):2035–2043

    Article  PubMed  Google Scholar 

  • Pavlakis N, Schmidt RL, Stockler MR (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474

    Google Scholar 

  • Rauschecker HHF, Clarke MJ, Gatzemeier W, Recht A (2001) Systemic therapy for treating locoregional recurrence in women with breast cancer. Cochrane Database Syst Rev 2001(4):CD002195

    Google Scholar 

  • Robert Koch-Institut – RKI (2010) Krebs in Deutschland 2007/2008. Häufigkeiten und Trends. Eine gemeinsame Veröffentlichung des Robert Koch-Instituts und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., 8. Aufl. Robert Koch-Institut, Berlin

    Google Scholar 

  • Robson M, Goessl C, Domchek S (2017) Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. N Engl J Med 377(18):1792–1793

    Google Scholar 

  • Ross JR, Saunders Y, Edmonds PM et al (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327:469–474

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rutgers EJ, van Slooten EA, Kluck HM (1989) Follow-up after treatment of primary breast cancer. Br J Surg 76(2):187–190

    Article  CAS  PubMed  Google Scholar 

  • Schmoor C, Sauerbrei W, Bastert G, Schumacher M (2000) Role of isolatedclocoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 18:1696–1708

    Article  CAS  PubMed  Google Scholar 

  • Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446–1452

    Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shaks S, Fuchs H, Paton V, Bajamonde A (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  • Sledge GW, Hu P, Falkson G et al (2000) Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an eastern cooperative oncology group study. J Clin Oncol 18:262–266

    Article  CAS  PubMed  Google Scholar 

  • Stockler M, Wilcken N, Ghersi D, Simes RJ (2000) Systematic review of systemic therapie for advanced breast cancer. Cancer Treat Rev 26:168

    Article  Google Scholar 

  • Waeber M, Castiglione-Gertsch M, Dietrich D et al (2003) Swiss Group for Clinical Cancer Research (SAKK): adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14(8):1215–1221

    Article  CAS  PubMed  Google Scholar 

  • Wapnir IL et al (2017) Poor prognosis after second locoregional recurrences in the CALOR trial. Ann Surg Oncol 24(2):398–406

    Google Scholar 

  • Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003(2):CD002747

    Google Scholar 

  • Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103(3):250–263

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle (Saale), Halle (Saale), Deutschland

    Eva J. Kantelhardt, Martina Vetter & Hans-Georg Strauß

Authors
  1. Eva J. Kantelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Vetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans-Georg Strauß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva J. Kantelhardt .

Editor information

Editors and Affiliations

  1. Fürst-Stirum-Klinik Bruchsal Frauenklinik, Bruchsal, Germany

    Jürgen Wacker

  2. Praxisklinik am Rosengarten, Mannheim, Germany

    Martin Sillem

  3. Praxisklinik am Rosengarten, Mannheim, Germany

    Gunther Bastert

  4. Frauenklinik, Universitätsklinikum Erlangen-Nürnberg Frauenklinik, Erlangen, Germany

    Matthias W. Beckmann

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kantelhardt, E.J., Vetter, M., Strauß, HG. (2020). Mammakarzinomrezidiv und metastasiertes Mammakarzinom. In: Wacker, J., Sillem, M., Bastert, G., Beckmann, M. (eds) Therapiehandbuch Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59809-2_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59809-2_32

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59808-5

  • Online ISBN: 978-3-662-59809-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation